Rajeev Singh, the Chief Executive Officer of Accolade, Inc. (NASDAQ:ACCD), recently executed a sale of company stock, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the stock trades at $3.58, down nearly 70% year-to-date, though InvestingPro analysis suggests the stock is currently undervalued. On December 11, Singh sold 667 shares of common stock at a price of $3.622 per share, amounting to a total transaction value of $2,415. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as per the filing. With a beta of 2.07, InvestingPro data shows the stock exhibits significant volatility compared to the broader market.
In addition to the sale, Singh acquired 1,650 shares of common stock on December 10 through the conversion of RSUs, though these transactions were executed at no cost. Following these transactions, Singh holds 815,299 shares directly and has indirect ownership of 651,619 shares through Avanti Holdings, LLC, where he has voting and investment power. For deeper insights into Accolade's valuation and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been the subject of several analysts' notes. Wells Fargo (NYSE:WFC) revised Accolade's price target downwards to $6.00, citing concerns over deal closures and their impact on the company's growth. Despite this, the firm maintained an Equal Weight rating, suggesting a balanced risk and reward profile for the stock. In the meantime, Accolade reported robust second-quarter results for 2025, with revenues of $106.4 million, exceeding expectations. The company also confirmed its revenue guidance for fiscal year 2025, ranging from $460 million to $475 million.
Stephens, Canaccord Genuity, Truist Securities, and BofA Securities also revised their price targets for Accolade, all maintaining Buy ratings. Stephens and Canaccord Genuity both expect a 12% revenue growth for Accolade in fiscal years 2025 and 2026. Canaccord Genuity expressed confidence in Accolade's ability to meet performance guarantees and secure new business, despite the company's third-quarter guidance falling below estimates.
Truist Securities and BofA Securities also adjusted their price targets, with Truist reducing its target to $7.50 from $9.00, and BofA lowering its target to $5.75 from $7.00. Despite these adjustments, both firms maintained Buy ratings, highlighting Accolade's strong pipeline of new business opportunities, particularly in health plans and government segments. These recent developments reflect the ongoing changes in Accolade's financial performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.